Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480852 | 1.00 | TSHR (0.64) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL31257672 | 0.86 | TSHR (0.53) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL3010961 | 0.84 | TDP1 (0.61) | TSHRSMN1; SMN2HSD17B10TDP1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28763100 | 0.82 | TDP1 (0.58) | TSHRSMN1; SMN2HSD17B10TDP1ALDH1A1 | |
| SCHEMBL29740027 | 0.81 | HSD17B10 (0.48) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL3391686 | 0.81 | HSD17B10 (0.48) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL307855 | 0.78 | TDP1 (0.54) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL29538967 | 0.78 | TSHR (1.00) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL6051840 | 0.78 | TSHR (0.69) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL29355089 | 0.78 | TDP1 (0.54) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574054-B | Preparation method of 2-fluoro-3-nitrobenzoic acid | 济南国鼎医药科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2026-03-24 | — | — | US | claimed |
| CN-121574054-A | Preparation method of 2-fluoro-3-nitrobenzoic acid | 济南国鼎医药科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250179005-A1 | CRYSTALLINE 2-FLUORO-3-NITROTOLUENE AND PROCESS FOR THE PREPARATION THEREOF | AMGEN INC. | 2025-06-05 | — | — | US | claimed |
| CN-112654602-B | Crystalline 2-fluoro-3-nitrotoluene and process for preparing the same | 意大利合成制造有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-114560774-B | Synthesis method of 2-fluoro-3-nitrobenzoic acid | 九洲药业(杭州)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119775143-A | Synthesis method of 2-fluoro-3-nitrobenzoic acid | 河北科技大学 | 2025-04-08 | — | — | CN | claimed |
| US-12162815-B2 | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2024-12-10 | — | — | US | claimed |
| EP-4305018-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117157274-A | Synthesis of olmesartan Mo Kabi mol | 安进股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-3477758-A1 | NONAQUEOUS ELECTROLYTE, POWER STORAGE ELEMENT, AND METHOD FOR PRODUCING POWER STORAGE ELEMENT | GS Yuasa International Ltd. (JP) | 2019-05-01 | — | — | EP | claimed |
| WO-2019006231-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-7651885-B2 | Electronic device fabrication process | XEROX CORPORATION (US) | 2010-01-26 | — | — | US | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| CN-101177400-A | Method for producing 2-fluorin-3-nitrotoluene | LU TIEHUAN (CN) | 2008-05-14 | — | — | CN | claimed |
| US-20070141747-A1 | Electronic device fabrication process | XEROX CORPORATION | 2007-06-21 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| US-4502995-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179005-A1 | CRYSTALLINE 2-FLUORO-3-NITROTOLUENE AND PROCESS FOR THE PREPARATION THEREOF | NOX5, NOX3, NOS2 | TSHR 4003/4885SMN1; SMN2 2663/4885HSD17B10 454/4885 |
| US-12162815-B2 | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof | NOX3, NOX5, NOS2 | TSHR 4074/4885SMN1; SMN2 2679/4885HSD17B10 477/4885 |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SLC28A2, SLC28A1, SLC5A11 | TSHR 2392/4885SMN1; SMN2 1614/4885HSD17B10 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.